| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3297405 | Gastroenterology | 2011 | 13 Pages |
Abstract
Patients with HCC treated by chemoembolization or radioembolization with Yttrium-90 microspheres had similar survival times. Radioembolization resulted in longer time-to-progression and less toxicity than chemoembolization. Post hoc analyses of sample size indicated that a randomized study with > 1000 patients would be required to establish equivalence of survival times between patients treated with these two therapies.
Keywords
European Association for Study of the Liveryttrium-90 microspheres90YTTPPVTEASLLocoregional therapiesBCLCIQRECoGRCTHCCα-fetoproteinRandomized controlled trialComparative effectivenessportal vein thrombosisAFPRadiotherapyTime-to-progressionWorld Health OrganizationLiver cancerUnited Network for Organ Sharingeastern cooperative oncology groupconfidence intervalinterquartile rangeResponse ratehazard ratioClinical trialHepatocellular carcinomaBarcelona Clinic Liver CancerWHOYttrium-90UNOS
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Riad Salem, Robert J. Lewandowski, Laura Kulik, Edward Wang, Ahsun Riaz, Robert K. Ryu, Kent T. Sato, Ramona Gupta, Paul Nikolaidis, Frank H. Miller, Vahid Yaghmai, Saad M. Ibrahim, Seanthan Senthilnathan, Talia Baker, Vanessa L. Gates, Bassel Atassi,